Learn how AI is changing the medtech industry and what it means for your company.
Posted by Clare Scott, Managing Editor – Manufacturing Group
Artificial intelligence (AI) in 2026 is now more than a buzzword. It’s reality in our everyday lives. It’s also impacting the medtech industry in interesting ways. But is AI truly creating value for our medtech businesses? Find out on May 13 at 12PM ET in the free webinar The Value of AI in MedTech – from Start-Up to Operational Excellence to M&A. Experts from MedWorld Advisors will explore the value impacts of AI in 2026 for medtech companies at all stages of growth – from start-up to scale-up including operational excellence through M&A exit.
Daniel Sheppard
Managing Director
MedWorld Advisors
Daniel Sheppard has spent nearly two decades advising founder-owned MedTech and finance companies in mergers and acquisitions, corporate finance, and strategic growth initiatives. He is currently a managing director at MedWorld Advisors. Daniel joined the MedWorld Advisors team in 2016 as a valuable asset in managing deal processes. Coming from a financial background with process and project management experience, Daniel’s unique skills have proven invaluable in managing dynamic and fast paced M&A processes. His creative and calculated M&A process inputs have guided past MWA clients to not only solidify company value but also maximize value creation that has exceeded client expectations.
Dave Sheppard
Managing Director
MedWorld Advisors
Dave Sheppard has been a leader in the medical device industry for more than 30 years. His experience includes positions such as GM and VP, as well as high impact sales and marketing leadership roles at major Fortune 500 corporations (Medtronic/Covidien, BD/Bard, Cooper and Ciba). His achievements also involve work at startup organizations (including working pre-IPO on a successful IPO company). As a managing director at MedWorld Advisors, Sheppard is focused on exit strategies for the MedDevice, BioTech, DentalTech, DigitalHealthTech, OEM Medtech, and anything Healthcare companies. Having completed international/cross-border deals, an important component to MedWorld’s success is its global reach and ability to cross boundaries to successfully facilitate transactions. In addition to M&A achievements at MedWorld Advisors, his MedTech career worldwide results include completing distribution and licensing deals with international businesses, comprising of major Fortune 500 companies (e.g., GE, Philips, Stryker, NK, Mindray, etc.) as well as smaller entities. These experiences have led to a global network of contacts with channel partners both large and small.
Register now